Brain tryptophan/serotonin perturbations in metabolic encephalopathy and the hazards involved in the use of psychoactive drugs

Advances in Experimental Medicine and Biology

Volumn 467, Issue , 2000, Pages 139-154

  Bengtsson, F ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN MONOAMINE; MELATONIN; OXINDOLE; PSYCHOTROPIC AGENT; QUINOLINIC ACID; SEROTONIN; TRYPTAMINE; TRYPTOPHAN;

AMINO ACID BRAIN LEVEL; CONFERENCE PAPER; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; HEALTH HAZARD; HUMAN; METABOLIC ENCEPHALOPATHY; NEUROTRANSMISSION; PHARMACODYNAMICS; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE;

ANIMALS; BRAIN; HEPATIC ENCEPHALOPATHY; HUMANS; INDOLES; PSYCHOTROPIC DRUGS; QUINOLINIC ACID; SEROTONIN; SYNAPTIC TRANSMISSION; TRYPTAMINES; TRYPTOPHAN;

EID: 0034466532     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (121)

1. Melatonin
2. Diurnal and gender effects by chronic portacaval shunting in rats on spontaneous locomotor and rearing activities in an open-field
3. Liver tryptophan pyrrolase. A major determinant of the lower brain 5-hydroxytryptamine concentration in alcohol-preferring C57BL mice
4. Serotonin metabolism in rat brain alter surgical diversion of the portal venous circulation
5. Trace amines and alternative neurotransmitters in the central nervous system
6. The relationship between plasma and brain quinolinic acid levels and the severity of hepatic encephalopathy
7. Quinolinic acid in children with congenital hyperammonemia
8. The pharmacokinetics of citalopram
9. Experimental hepatic encephalopathy. Changes of the level of wakefulness in the rat with portacaval shunt
10. Brain monoamine metabolism and behavior in portacaval-shunted rats
11. The impact of time after portacaval shunt in the rat on behavior, brain serotonin, and brain and muscle histology
12. Hepatocerebral dysfunction and brain serotonin
13. Brain tryptophan hydroxylation in the portacaval shunted rat: A hypothesis for the regulation of serotonin turnover in vivo
14. Neurotransmission failure in hepatic encephalopathy involving the combined action of different brain tryptophan-related pathology: A speculative synthesis
15. Neuropsychiatric implications of brain tryptophan: Perturbations appearing in hepatic encephalopathy
16. Mirtazapine oral single dose kinetics in patients with different degrees of renal impairment: Implications for antidepressant dosage and safety in nephrological health care
17. Aromatic and branched-chain amino acids in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy
18. Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy
19. Early changes of serotonin turnover in brain following portacaval anastomosis: Relation to altered sleep patterns and diurnal rhythms
20. Regional alterations of dopamine and its metabolites in rat brain following portacaval anastomosis
21. Night sleep organization in patients with severe hepatic failure. Its modifications after L-DOPA treatment
22. Brain quinolinic acid in chronic experimental hepatic encephalopathy: Effects of an exogenous ammonium acetate challenge
23. Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt
24. Brain extracellular quinolinic acid in chronic experimental hepatic encephalopathy as assessed by in vivo microdialysis: Acute effects of L-tryptophan
25. Acute effects of L-tryptophan on brain extracellular 5-HT and 5-HIAA in chronic experimental portal-systemic encephalopathy
26. Ammonium acetate challenge in experimental hepatic encephalopathy induces a transient increase of brain 5-HT release in vivo
27. Potassium-evoked neuronal release of 5-hydroxytryptamine in experimental portal-systemic encephalopathy
28. p-Chloroamphetamine and d-fenfluramine-induced brain serotonin release in experimental portal-systemic encephalopathy
29. Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: Implications for thymoleptic drug safety in liver insufficiency
30. The cerebral and peripheral uptake of ammonia in liver disease with an hypothesis for the mechanism of hepatic coma
31. A study of proposed determinants of brain tryptophan concentration in rat after portocaval anastomosis or sham operation
32. Behavioral, electroencephalographic, and biochemical changes in porta-cava shunted rats
33. The central-nervous-system toxicity of long-term oral administration of L-tryptophan to porto-caval-shunted rats
34. Hepatic encephalopathy
35. Oxindole, a sedative tryptophan metabolite, accumulates in blood and brain of rats with acute hepatic failure
36. Plasma and cerebrospinal fluid amino acid patterns in hepatic encephalopathy
37. Early changes in blood-brain barrier permeability after porto-caval shunt and liver ischaemia
38. Regional brain indoleamine metabolism following chronic portacaval anastomosis in the rat
39. Regional brain study of indoleamine metabolism in the rat in acute hepatic failure
40. Plasma and brain tryptophan changes in experimental acute hepatic failure
41. Effects of chronic porto-caval anastomosis on brain tryptophan, tyrosine and 5-hydroxytryptamine
42. Pharmacokinetics of paroxetine in patients with cirrhosis
43. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease
44. Pharmacokinetics of newer antidepressants: Clinical relevance
45. Pharmacological effects of p-chloroamphetamine with respect to current amine hypotheses of affective disorders
46. Brain dialysis of neurotransmitters: A commentary
47. Sertraline: A new antidepressant
48. Evidence for central hypertyraminemia in hepatic encephalopathy
49. Reduced nocturnal melatonin secretion in chronic schizophrenia: Relationship to body weight
50. Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses
51. False neurotransmitters and hepatic failure
52. Plasma amino acids in patients with hepatic encephalopathy. Effects of amino acid infusions
53. Kinetics of citalopram in man: Plasma levels in patients
54. Kynurenine metabolites of tryptophan: Implications for neurologic diseases
55. Cyclosporin A but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death
56. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease
57. Pharmacokinetics of second generation antidepressants: Fluoxetine
58. Symptoms and signs of severe citalopram overdose
59. Studies on the metabolism of amino acids and related compounds in vivo. I. Toxicity of essential amino acids, individually and in mixtures, and the protective effect of L-arginine
60. New antidepressants: Use in high-risk patients
61. Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts
62. Thryptophan metabolism in liver disease
63. Safety of fluvoxamine for patients with chronic liver disease
64. Failure of selective serotonin re-uptake inhibition to worsen the mental state of patients with subclinical hepatic encephalopathy
65. A longitudinal study of tryptophan involvement in hepatic coma
66. Hyperammonemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: A unified theory of portal-systemic encephalopathy
67. Brain monoamines in metabolic (endotoxic) coma. A preliminary biochemical study in human postmortem material
68. Brain monoamines in hepatic encephalopathy and other types of metabolic coma
69. Hyperammonemia causes many of the changes found after portacaval shunting
70. Dopamine and serotonin metabolism in hepatic encephalopathy
71. The pharmacokinetics of paroxetine in patients with liver cirrhosis
72. Portacaval shunt in the rat
73. Plasma melatonin in manic-depressive illness
74. Correlation of plasma and brain amino acid and putative neurotransmitter alterations during acute hepatic coma in the rat
75. Regional blood-brain barrier permeability to amino acids after portacal anastomosis
76. Brain monoamines after portacaval anastomosis
77. Receptors for the excitatory amino acids in the mammalian central nervous system
78. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease
79. Content of quinolinic acid and of other tryptophan metabolites increases in brain regions of rats used as experimental models of hepatic encephalopathy
80. Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure
81. Tryptamine: A metabolite of tryptophan implicated in various neuropsychiatric disorders
82. 3H]tryptamine binding sites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy
83. Tryptophan and hepatic coma
84. The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis
85. Kinetics of competitive inhibition of neutral amino acid transport across the bloodbrain barrier
86. Pharmacology and regional variations of quinolinic acid-evoked excitations in the rat central nervous system
87. 3H]glutamate binding sites in rat brain following portacaval anastomosis
88. Quinolinate in brain and cerebrospinal fluid in rat models of congenital hyperammonemia
89. Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis
90. Amino acid, ammonia and neurotransmitter concentrations in hepatic encephalopathy: Serial analysis in plasma and cerebrospinal fluid during treatment with an adapted amino acid solution
91. Alterations of plasma and brain tryptophan in hepatic encephalopathy: A study in humans and in experimental animals
92. Permeability of the blood-brain barrier after portocaval anastomosis in the rat
93. Cerebral adenosine triphosphate in rats with ammonia-induced coma
94. Fluoxetine disposition and elimination in cirrhosis
95. Neurotransmitter changes in the rat brain after portacaval anastomosis
96. Alterations in plasma and CSF amino acids, amines and metabolites in hepatic coma
97. Why are plasma branched chain amino acid levels diminished in patients with liver cirrhosis?
98. Drug metabolism in liver disease: Implications for therapeutic drug monitoring
99. Disruption of circadian locomotor activity in rats after portacaval anastomosis is not gender dependent
100. Disruption of the diurnal rhythm of plasma melatonin in cirrhosis
101. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function
102. Neuropharmacology of quinolinic and Kynurenic acids
103. Intracellular pH rises and astrocytes swell after portacaval anastomosis in rats
104. Gender and diurnal effects on specific open-field behavioral patterns in the portacaval shunted rat
105. Effects of chronic experimental liver dysfunction and L-tryptophan on behavior in the rat
106. Measurement of neurotransmitter release by intracranial dialysis
107. The acquired (non-Wilsonian) type of chronic hepatocerebral degeneration
108. Neurologic changes in liver disease
109. Neurologic disorders due to alcoholism and malnutrition
110. Scope and limitations of in vivo brain dialysis: A comparison of its application to various neurotransmitter systems
111. Melatonin and cortisol levels in psychiatric illness
112. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system
113. Brain Monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy
114. Relationships between tryptophan in serum and CSF, and 5-hydroxyindoleacetic acid in CSF of man: Effect of cirrhosis of liver and probenecid administration
115. CNS tryptamine metabolism in hepatic coma
116. Portacaval anastomosis disrupts circadian locomotor activity and pineal melatonin rhythms in rats